GU Cancers 2019 | CTCs in metastatic GU cancer: association with clinical outcomes?

Andrea Apolo

Andrea Apolo, MD, of the National Cancer Institute, Bethesda, MD, speaks at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA. She discusses her group’s investigation of circulating tumor cells (CTCs) in patients with metastatic genitourinary tumors treated in a Phase I study of cabozantinib and nivolumab +/- ipilimumab. This included the association between baseline CTC enumeration, change in CTC enumeration post-treatment, PFS, OS and response to treatment.

Share this video